Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are over 18 years of age
- People who have been diagnosed with a neuroendocrine tumour (NET) that started in the stomach, intestines, or pancreas, and whose treating doctor has agreed they should receive a treatment called PRRT (a type of targeted radiation therapy)
- People whose tumour has spread to other parts of the body, or has grown locally in a way that cannot be removed with surgery
- People whose disease has clearly gotten worse while on a medication called Octreotide, within a period of less than 3 years (as measured by standard imaging guidelines called RECIST 1.1)
- People who have had specialised scans (Ga-68 DOTATATE PET/CT and/or FDG PET/CT) within the past 24 weeks that show active disease
- People whose tumour is considered "well differentiated" and has a growth rate marker (Ki67) of less than 20%
- People whose tumour responds to Octreotide, either confirmed on a tissue sample or shown on the specialised DOTATATE scan
- People whose recent blood test results fall within the following ranges: creatinine (a kidney marker) below 1.7, haemoglobin (red blood cells) above 8, white blood cell count above 2,000, platelet count above 75,000, and bilirubin (a liver marker) less than 3 times the upper normal limit
- People who have not taken Octreotide within 30 days before the treatment is given
- People who are willing and able to follow all study requirements
- People who are able to understand and sign the consent form in English
- Note: People with a NET that started somewhere other than the stomach, intestines, or pancreas may be considered on a case-by-case basis if their DOTATATE scan is positive and all other criteria are met (confirm with trial site)
Who may not be able to join:
- People who do not meet the inclusion criteria listed above
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alejandro Mejia, MD, Liver Institute at Methodist Dallas Medical Center
Phone: 214-947-1280
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Demographics and other patient data; Tumor specific data; Use of somatostatin analogs; Biomarker data (chromogranin A and pancreastatin); Diagnostic imaging findings; Overall survival (OS); Time to progression (TTP); Treatment responses and progression; Response; Disease progression; Adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.